source
- J&J to acquire Firefly Bio for $1 billion, adding degrader-antibody conjugate technologyJ&J announced it will acquire biotech startup Firefly Bio in an all‑cash transaction valued at $1 billion. The deal gives J&J access to Firefly’s degrader‑antibody conjugate platform, which blends…
- City Therapeutics secures $99.5 million to advance RNAi drugs targeting clotting disorder and Stargardt diseaseCity Therapeutics, a young biotech focused on RNA interference therapies, announced it has raised $99.5 million to support further development of its pipeline. The funding will back its lead candid…